OncoMatch/Clinical Trials/NCT06612151
A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer
Is NCT06612151 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including YL201 and topotecan hydrochloride for for small cell lung cancer.
Treatment: YL201 · topotecan hydrochloride for — This study was designed to compare the efficacy and safety of YL201 with Topotecan Hydrochloride in subjects with relapsed small cell lung cancer (SCLC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Biomarker criteria
Required: CD276 any tested (testing required; no eligibility threshold specified)
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy — first-line
Cannot have received: b7-h3-targeted therapy
Cannot have received: topoisomerase i inhibitor
Lab requirements
Blood counts
Adequate organ function
Kidney function
Adequate organ function
Liver function
Adequate organ function
Adequate organ function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify